<DOC>
	<DOCNO>NCT02499081</DOCNO>
	<brief_summary>The purpose study evaluate effect Ixazomib induce osteoblast activation measure bone marker image patient relapsed/refractory myeloma .</brief_summary>
	<brief_title>UARK 2014-14 : Phase II Prospective Evaluation Bone Remodeling During Ixazomib Treatment</brief_title>
	<detailed_description>This phase II study design examine bone anabolic effect next generation proteasome inhibitor , ixazomib , relapsed/refractory myeloma patient . Treatment consist Ixazomib 4 mg day 1 , 8 , 15 , 22 28 day cycle , maximum 6 cycle . Determination relapsed/refractory disease entry criterion may base patient data obtain follow patient 's recent prior antineoplastic therapy . Treatment period define 28-day cycle . Patients see regular interval participate study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year old . Voluntary write consent must give performance study relate procedure part standard medical care , understand consent may withdraw patient time without prejudice future medical care . Female patient : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 90 day last dose study drug , AND Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Male patient , even surgically sterilize ( ie , status postvasectomy ) , must agree one following : Agree practice effective barrier contraception entire study treatment period 90 day last dose study drug , OR Agree practice true abstinence line prefer usual lifestyle subject . ( Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception . ) Patients must diagnosis relapsed/refractory multiple myeloma must receive least one line prior therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status and/or performance status 0 , 1 , 2 . Patients must meet follow clinical laboratory criterion : Absolute neutrophil count ( ANC ) 1,000/mm3 platelet count 75,000/mm3 . Platelet transfusion help patient meet eligibility criterion allow within 3 day study enrollment . Total bilirubin1.5 upper limit normal range ( ULN ) . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) 3 ULN . Calculated creatinine clearance 30 mL/min . Female patient lactate positive serum pregnancy test screening period . Failure fully recover ( ie , Grade 1 toxicity ) reversible effect prior chemotherapy . Major surgery within 14 day enrollment . Radiotherapy within 14 day enrollment . If involved field small ( opinion enrol investigator ) , 7 day consider sufficient interval treatment administration ixazomib . Patients nonmyeloma related bone disease interfere interpretation bonerelated blood radiology assessment , include Paget 's disease , Rickets , Osteomalacia , metastatic bone cancer . History myelomarelated central nervous system involvement . Infection require systemic antibiotic therapy serious infection within 14 day study enrollment . Evidence current uncontrolled cardiovascular condition , include uncontrolled hypertension , uncontrolled cardiac arrhythmia , symptomatic congestive heart failure , unstable angina , myocardial infarction within past 6 month . Systemic treatment , within 14 day first dose ixazomib , strong inhibitor CYP1A2 ( fluvoxamine , enoxacin , ciprofloxacin ) , strong inhibitor CYP3A ( clarithromycin , telithromycin , itraconazole , voriconazole , ketoconazole , nefazodone , posaconazole ) strong CYP3A inducer ( rifampin , rifapentine , rifabutin , carbamazepine , phenytoin , phenobarbital ) , use Ginkgo biloba St. John 's wort . Ongoing active systemic infection , know active hepatitis B C virus infection , know human immunodeficiency virus ( HIV ) positive . Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol . Known allergy study medication , analogue , excipients various formulation agent . Known GI disease history GI procedure could interfere oral absorption tolerance ixazomib include difficulty swallowing . Diagnosed treat another malignancy within 2 year study enrollment previously diagnose another malignancy evidence residual disease . Patients nonmelanoma skin cancer carcinoma situ type exclude undergone complete resection . Patient Grade 3 peripheral neuropathy , Grade 2 pain clinical examination screen period . Participation clinical trial , include investigational agent include trial , within 21 day start trial throughout duration trial . Patients take bisphosphonate RANK Ligand Inhibitor within 3 week screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Proteasome Inhibitor</keyword>
</DOC>